IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5

Early virological response End-of-treatment virological response Sustained virological response Age (continuous) 0.95 (0.82 to 1.09) 0.5 0.97 (0.88 to 1.07) 0.5 0.95 (0.89 to 1.01) 0.11 Male sex - - 4.38 (0.45 to 42.40) 0.2 1.50 (0.49 to 4.64) 0.5 BMI (continuous) 1.95 (0.96 to 3.95) 0.06 1.96 (1.10...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2012-11, Vol.61 (11), p.1640-1641
Hauptverfasser:	Antaki, Nabil, Bibert, Stéphanie, Kebbewar, Kamel, Asaad, Fouad, Baroudi, Osama, Alideeb, Sawsan, Hadad, Milad, Abboud, Dirar, Sabah, Houda, Bochud, Pierre-Yves, Negro, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	achalasia acute pancreatitis Antiviral Agents - therapeutic use antiviral therapy autoimmune liver disease bile duct stones biliary endoscopy Body mass index colonic polyps Crohn's disease Female genetic polymorphisms Hepacivirus - genetics hepatic fibrosis Hepatitis hepatitis A hepatitis B Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy hepatitis D hepatitis E hepatocellular carcinoma Humans Interferon Interleukins - genetics Liver cirrhosis Male Polymorphism, Single Nucleotide Response rates
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!